Myricetin attenuates hypoxic-ischemic brain damage in neonatal rats via NRF2 signaling pathway
Frontiers in Pharmacology · 08.03.2023 · 14
DOI: 10.3389/fphar.2023.1134464 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 08.03.2023. Verfasst von Tingting Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The Second School of Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University,…. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Hypoxic-ischemic encephalopathy (HIE) is a crucial cause of neonatal death and neurological sequelae, but currently there is no effective therapy drug for HIE. Both oxidative stress and apoptosis play critical roles in the pathological development of HIE. Myricetin, a naturally extracted flavonol compound, exerts remarkable effects against oxidative stress, apoptosis, and inflammation. However, the role and underlying molecular mechanism of myricetin on HIE remain unclear.
Methods
In this study, we established the neonatal rats hypoxic-ischemic (HI) brain damage model in vivo and CoCl 2 induced PC1 2 cell model in vitro to explore the neuroprotective effects of myricetin on HI injury, and illuminate the potential mechanism.
Results
Our results showed that myricetin intervention could significantly reduce brain infarction volume, glia activation, apoptosis, and oxidative stress marker levels through activating NRF2 (Nuclear factor-E2-related factor 2) and increase the expressions of NRF2 downstream proteins NQO-1 and HO-1. In addition, the NRF2 inhibitor ML385 could significantly reverse the effects of myricetin.
Conclusion
This study found that myricetin might alleviate oxidative stress and apoptosis through NRF2 signaling pathway to exert the protective role for HI injury, which suggested that myricetin might be a promising therapeutic agent for HIE.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, The Second School of Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Key Laboratory of Perinatal Medicine of Wenzhou, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Basic Medical Research Center, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Key Laboratory of Structural Malformations in Children of Zhejiang Province, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Key Laboratory of Children Genitourinary Diseases of Wenzhou, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Zitieren
APA
Chen, T., Hu, Y., Lu, L., Zhao, Q., Tao, X., Ding, B., Chen, S., Zhu, J., Guo, X., & Lin, Z. (2023). Myricetin attenuates hypoxic-ischemic brain damage in neonatal rats via NRF2 signaling pathway. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1134464
Vancouver
Chen T, Hu Y, Lu L, Zhao Q, Tao X, Ding B, et al. Myricetin attenuates hypoxic-ischemic brain damage in neonatal rats via NRF2 signaling pathway. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1134464
BibTeX
@article{Chen2023,
author = {Chen, Tingting and Hu, Yingying and Lu, Liying and Zhao, Qianlei and Tao, Xiaoyue and Ding, Bingqing and Chen, Shangqin and Zhu, Jianghu and Guo, Xiaoling and Lin, Zhenlang},
title = {Myricetin attenuates hypoxic-ischemic brain damage in neonatal rats via NRF2 signaling pathway},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1134464}
}
EUVIMED